hotspot -WSS

hotspot

author：entertainment 2025-09-27 10:02:59 - browse：79

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Shifting the focus from loneliness to social health

focus

Wikipedia

WSS

Cord blood banking comes at a high cost to babies

Letters to First Opinion on caregivers, digital health, and more

What to make of Biden’s latest efforts on cancer research

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Regeneron agrees to White House price limits on anti

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

explore

hotspot

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Telehealth for opioid use disorder is lifesaving

How to save PrEP access — and even expand it

New Covid vaccine is recommended for everyone 6 months or older

Hepatitis C has a cure — but many Americans still lack access to it

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

How to save PrEP access — and even expand it

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Cancer drug shortages should be causing more outrage

Cord blood banking comes at a high cost to babies

entertainment

Change Healthcare can notify patients about the breach, HHS says

Long Covid needs a new name — and a new frame

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Shifting the focus from loneliness to social health

How housing is health care on Long Island

White House touts steps to stem shortages of cancer treatments

focus

focus

Wikipedia

leisure time